There are 4 papers on albumin-bilirubin grade in aging research: 1 trial and 3 observational studies in people.
4 papers study it1 finding
“ALBI grade ≥2 (aHR = 2.13, 95% CI: 1.17 to 3.90, P = 0.014)”
- Human trial1
- Humans3
Associations
1Mortality
upin humans1
1 study
Mortality
upin humans1
Albumin-bilirubin grade predicts mortality in humans (ALBI grade ≥2 vs <2 in PLWH after DAA-induced SVR) (aHR 2.13, 95% CI: 1.17 to 3.90).
“ALBI grade ≥2 (aHR = 2.13, 95% CI: 1.17 to 3.90, P = 0.014)”
HumansALBI grade ≥2 vs <2 in PLWH after DAA-induced SVR
Non-liver Malignancies as Main Cause of Mortality After HCV Eradication Among People Living With HIV
Journal of acquired immune deficiency syndromes (1999)
Latest
1 paper in 12 monthsResearch Square
The Risk Mechanism Theory Index (RMTI) as a Triage and Evidence-Grading Layer for Hepatocellular-Carcinoma Surveillance A transparent, computable model for the diagnosis-to-detection-to-management cascade, with an open calculator and a real-data demonstration
Preprint: study in peopleHepatocellular carcinoma
Clinical Nutrition ESPEN
An open-label, randomized, controlled trial on the benefit of β-hydroxy-β-methyl butyrate, l-arginine, l-glutamine combination beverages and locomotion training as supportive care for the treatment of unresectable hepatocellular carcinoma using lenvatinib: A pilot study (HELLO study)
Randomized trial in 20 peopleHepatocellular carcinoma
Journal of Acquired Immune Deficiency Syndromes
Non-liver Malignancies as Main Cause of Mortality After HCV Eradication Among People Living With HIV
Cohort study of 663 peopleCancer
ESMO Gastrointestinal Oncology
The Liver Frailty Index predicts survival in systemic therapy for hepatocellular carcinoma: a multicentre prospective cohort study
Cohort study of 102 peopleLiver Frailty Index